



Bristol-Myers Squibb Company
Patent Department

RECEIVED
CENTRAL FAX CENTER

JUN 22 2006

FACSIMILE TRANSMITTAL SHEET

DATE: June 22, 2006
TO: Examiner Joseph Kosack, USPTO
FACSIMILE NO.: 571-273-8300
FROM: Laurelee A. Duncan
TELEPHONE NO.: (609) 252-5323
FACSIMILE NO.: (609) 252-4526
COMPANY: Bristol-Myers Squibb Company
Number of Pages: 46 (including cover sheet)

If you do not receive a complete fax, please contact Tina Markee.
Telephone: (609) 252-4300.

COMMENTS:

U.S. Application no. 10/776,828
Attorney Docket No. PH 7442 NP

This document contains privileged client-attorney communications. The information is intended to be for the use of the addressee only. If you are not the addressee, note that any disclosure, copy, distribution or use of the contents of this document is prohibited.

If you have received this message in error, please notify the sender of the error and delete the message. Thank you.

CONFIDENTIALITY NOTICE — This document is intended only for the person(s) named in the message header. Unless otherwise indicated, it contains information that is confidential, privileged and/or exempt from disclosure under applicable law. If you have received this message in error, please notify the sender of the error and delete the message. Thank you.

RECEIVED
CENTRAL FAX CENTER

PH-7442-NP

JUN 22 2006

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office (571-273-8300) on the date shown below.

Laurelee A. Duncan
Type or print name

Laurelee A. Duncan
Signature

June 22, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1626

ROBERT CHERNEY, ET AL

EXAMINER: KOSACK, JOSEPH R

APPLICATION NO: 10/776828

FILED: 02/11/2004

FOR: CYCLIC DERIVATIVES AS MODULATORS OF
CHEMOKINE RECEPTOR ACTIVITY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL

Sir:

In response to the Office Action dated April 26, 2006, and the telephone interview conducted on June 12, 2006, please amend the above identified patent application as follows: please amend claims 25 and 29; and please delete claims 23 and 24. Entry of these amendments prior to further prosecution of the application is respectfully requested.

"Amendments to the Claims" are represented by the listing of Claims which begin on page 2 of this paper. The "Interview Summary" begins on page 40 and the "Remarks" begin on page 42 of this paper.